Lung Cancer, Nonsmall Cell Clinical Trial
— GPSOfficial title:
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung Tumors Using Real-Time Tumor Tracking & Respiratory Gating: A Seamless Phase I/II Prospective Clinical Trial
Verified date | March 2024 |
Source | CancerCare Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single arm seamless phase I/II prospective cohort study. Patients with early stage Non-Small Cell Lung Cancer (T1-T2N0M0) or those with a single pulmonary metastasis of a known malignancy (either following radical treatment or systemic therapy) will be offered participation in this study. Participants will have three tumor locator beacons placed with a flexible bronchoscope in the small bronchial airways in proximity (<3cm) from their lung tumors. These tumor locator beacons will provide real-time positional data and will allow for smaller treatment volumes of Stereotactic Ablative Radiosurgery (SABR) and also allow for a specialized form of treatment delivery known as respiratory gated SABR. This is expected to result in higher precision radiotheapy delivery with less radiotherapy dose to healthy tissues which are in close proximity to the lung tumours.
Status | Active, not recruiting |
Enrollment | 28 |
Est. completion date | January 14, 2025 |
Est. primary completion date | January 14, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Adult = 18 years of age who is surgically inoperable, or refusing surgical management. 2. Tumor criteria (a patient must satisfy one of "a", "b" below to be eligible): 1. AJCC 7th edition clinical T1aN0M0, T1bN0M0, or T2aN0M0 (<4cm) Non-small cell lung cancer (adenocarcinoma, squamous cell carcinoma, or NSCLC Not Otherwise Specified) of the middle or lower lobes of the lung*; 2. A single pulmonary metastasis (<4cm) of a known primary malignancy of any histology involving the middle or lower lobes of the lung* (either metastatic failure to a single pulmonary site after primary radical treatment, metastatic progression to a single lung metastasis following palliative chemotherapy, or a single pulmonary metastatic lesion of newly diagnosed stage IV malignancy). - upper lobe tumors are eligible for trial participation if the tumor has a demonstrated tumor motion of =1 cm in any axis (as assessed by fluoroscopy at the time of bronchoscopy). 3. Confirmation of malignancy (a patient must satisfy one of "a", "b" below to be eligible): 1. Tumors accessible by bronchoscopy, image-guided percutaneous biopsy, or other invasive staging methods require biopsy confirmation of malignancy. 2. If a tumor is not amenable to a diagnostic biopsy, evidence of growth of the target tumor on serial imaging scans is necessary prior to enrollment. An increase in SUV of the target tumor on serial PET scans is also acceptable. 4. ECOG performance status of 0 to 2. 5. Minimum life expectancy of 6 months. 6. Deemed fit to undergo bronchoscopy by their participating thoracic surgeon 7. Deemed fit to undergo SABR by their participating Radiation Oncologist. 8. Respiratory function (a patient must satisfy both "a" and "b" below): 1. Minimum FEV1 of 0.8 liters 2. Minimum DLCO of 35% predicted. 9. Able to provide written informed consent and understand verbal instructions necessary for radiotherapy treatments. Exclusion Criteria: 1. Tumors located < 1cm from the chest wall based on CT imaging. 2. Tumors located = 2 cm from the proximal bronchial tree (see figure 7) 3. Patients who require supplemental oxygen at rest. 4. Patients who are unable to lie flat or still for a minimum of 30 minutes. 5. ECOG performance status 3 or 4. 6. Evidence of uncontrolled extra-thoracic metastatic disease (based on imaging or clinical findings). 7. Proven or suspected intrathoracic lymph node involvement. 8. Prior SABR to the target tumor. 9. Prior history of idiopathic pulmonary fibrosis, interstitial lung disease, or active collagen vascular disease (systemic lupus erythematosus, Rheumatoid arthritis, or Scleroderma) 10. Pregnancy. 11. Active pulmonary infection 12. Known hypersensitivity to nickel titanium (Nitinol) 13. Known Bronchiectasis of the small airways nearest to the tumor |
Country | Name | City | State |
---|---|---|---|
Canada | CancerCare Manitoba | Winnipeg | Manitoba |
Canada | Health Sciences Center | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
CancerCare Manitoba | Varian Medical Systems |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean within patient difference in PTV volumes | Mean within patient difference in PTV volumes of standard non-gated SABR treatment compared to PTV volumes of gated SABR using Calypso based PTV margins | Assessed Immediately prior to RT start | |
Secondary | Patient self-reported quality of life | EORTC QLQ - LC13 questionnaire | 1, 2, and 3 year | |
Secondary | Acute and late toxicity assessment using the Common Terminology Criteria for Adverse Events (CTCAE version 4.0) | Common Terminology Criteria for Adverse Events (CTCAE version 4.0) | 1, 2, and 3 year | |
Secondary | RT doses to Thoracic Organs at Risk | Mean within patient difference in radiotherapy doses to thoracic Organs at risk | Assessed Immediately prior to RT start | |
Secondary | Tumour Local Control | Local Control (RECIST version 1.1 criteria) | 1, 2, and 3 year | |
Secondary | Progression Free Survival | Progression Free Survival | 1,2, and 3 year | |
Secondary | Overall Survival | Overall Survival | 1,2, and 3 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06003075 -
Induction Chemo-Nivo in Unresectable Stage III NSCLC
|
Phase 2 | |
Enrolling by invitation |
NCT06293833 -
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
|
N/A | |
Recruiting |
NCT03705806 -
Palliative Thoracic ImmunoRT
|
||
Not yet recruiting |
NCT06060964 -
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
|
Early Phase 1 | |
Completed |
NCT04634630 -
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
|
||
Completed |
NCT03689634 -
Move For Surgery - A Novel Preconditioning Program
|
Phase 3 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Completed |
NCT03902834 -
Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery
|
N/A | |
Completed |
NCT02995889 -
FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
|
N/A | |
Recruiting |
NCT04237805 -
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
Suspended |
NCT02991651 -
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
|
Phase 1 | |
Enrolling by invitation |
NCT04678440 -
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
|
Early Phase 1 | |
Recruiting |
NCT04222335 -
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
|
N/A | |
Recruiting |
NCT04415320 -
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
|
Phase 2 | |
Recruiting |
NCT02786589 -
Plasmodium Immunotherapy for Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05085028 -
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
Completed |
NCT05956782 -
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
|
N/A | |
Enrolling by invitation |
NCT05863013 -
Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer
|
N/A |